FDA expands Fasenra label to hypereosinophilic syndrome

AstraZeneca’s Fasenra has picked up a new US FDA approval, this time for hypereosinophilic syndrome. On May 13, 2026, the agency approved benralizumab for adults and pediatric patients age 12 and older with HES without an identifiable non-hematologic secondary cause, adding a third US indication to a product already established in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. The new label recommends 30 mg subcutaneously every four weeks for HES. (accessdata.fda.gov)

The approval builds on a longer arc for benralizumab in eosinophilic disease. Fasenra first reached the US market in 2017 for severe eosinophilic asthma, then expanded into EGPA in 2024, while HES had remained an area of unmet need despite earlier clinical signals and off-label use. FDA orphan drug records show benralizumab received orphan designation for HES in February 2019, underscoring how long the company has been pursuing this rare-disease opportunity. (accessdata.fda.gov)

The pivotal evidence came from the phase 3 NATRON trial, a randomized, double-blind, placebo-controlled study in patients with FIP1L1::PDGFRA-negative HES. Its primary endpoint was time to first HES flare over 24 weeks. According to the published Nature Medicine report, 19.4% of patients receiving benralizumab experienced a flare, compared with 42.4% of those on placebo, translating to a 65% reduction in risk of first flare. The study also met its key secondary endpoints: fewer patients flared or withdrew, and the annualized flare rate was reduced by 66%, from 1.23 flares per year on placebo to 0.41 on benralizumab. (nature.com)

The label and trial details add practical context. FDA prescribing information lists the HES indication specifically for patients without an identifiable non-hematologic secondary cause, and the most common adverse reactions reported for HES were headache, hypersensitivity reactions, and influenza-like illness. The label also carries familiar biologic warnings around hypersensitivity, corticosteroid tapering, and helminth infection management. (accessdata.fda.gov)

Industry and investigator commentary has framed the decision as meaningful because HES is both rare and heterogeneous, making treatment pathways uneven. Reporting that summarized AstraZeneca’s announcement cited Princess Ogbogu, principal investigator of NATRON, calling the approval an important additional option for patients with HES. That aligns with the published trial’s discussion, which notes that while mepolizumab’s earlier approval improved outcomes, treatment responses still vary and additional options are needed. (drugs.com)

Why it matters: While this is a human drug approval, veterinary professionals following regulation and specialty therapeutics should see it as part of a larger story: immunology biologics are moving into narrower, more precisely defined inflammatory and hematologic conditions. That matters for companion animal medicine because specialty clinicians, industry strategists, and informed pet parents are increasingly aware of targeted monoclonal antibodies as mainstream medicine, not fringe innovation. The more these agents prove they can control disease flares and reduce steroid burden in people, the more pressure there may be to develop, adapt, or compare similarly targeted approaches in veterinary dermatology, internal medicine, and oncology. This is an inference based on the broader expansion of eosinophil-directed biologics across indications, rather than a direct claim from the FDA or AstraZeneca. (accessdata.fda.gov)

There’s also a market signal here. Fasenra now spans asthma, EGPA, and HES in the US, giving AstraZeneca a broader eosinophilic-disease franchise and deeper footing with allergy, pulmonology, rheumatology, and hematology specialists. For anyone watching translational medicine, that kind of franchise expansion often shapes future research investment, physician familiarity, and reimbursement strategy. (accessdata.fda.gov)

What to watch: Near term, the key questions are how quickly payers incorporate the new HES indication, whether treatment guidelines and specialty societies update recommendations, and how regulators outside the US move. The European Medicines Agency’s CHMP already adopted a positive opinion for Fasenra in HES on May 21, 2026, suggesting broader regulatory momentum may follow. (ema.europa.eu)